In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroPharmacokinetics and tissue penetration of enoxacinIn vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimIn vitro and in vivo antibacterial activity of AM-833, a new quinolone derivativeIn vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinoloneIn vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinoloneIntravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivativePenetration of enoxacin into bronchial secretions.The Salmonella typhimurium mar locus: molecular and genetic analyses and assessment of its role in virulence.In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humansOverexpression of the MarA positive regulator is sufficient to confer multiple antibiotic resistance in Escherichia coli.Proposed quality control and interpretive criteria for disk diffusion susceptibility testing with enoxacin.A review of the antimicrobial activity of the fluoroquinolones.Characterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibility1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities.Bone penetration of enoxacin in patients with and without osteomyelitis.Emergence of fluoroquinolone resistance in Bacteroides fragilis accompanied by resistance to beta-lactam antibiotics.Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureusComparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli.In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.
P2860
Q24670241-EFBCA752-96A5-46D8-ABE2-0F200F45DAF8Q24674802-6FC67C46-4314-437E-9F04-EEDBAAFE646EQ24677059-68F24382-36E0-453C-BA4E-D9C01FA7C6A6Q24685742-603EB27A-7332-47E9-96CE-546E33506518Q28326997-10066ED4-34E7-4724-BF0D-646D4393904DQ28359688-0AFA1EC1-A442-4D58-8D0C-7D45F9C232C5Q34417655-F56D731E-B267-4223-B9F0-32AAA58DF7BDQ34719806-21C6860F-4A9E-4E92-AC1D-461469A6ED65Q35340351-A0382DA6-0697-4DC3-AFDB-CF82922DC10AQ35540058-8FC4DC33-BBDD-4F93-BE29-F717E1455DC5Q35620892-6C745A13-1DC9-4470-826F-2359BC005A7EQ35639658-9C284436-8A1D-4134-A568-9E65CAC2F127Q35640867-301813BD-0BA5-4DC7-BA0B-0CD2784945EDQ35643969-907CB86D-150A-4A5F-9807-A224C58A038EQ35646442-162AD922-A4B7-487A-887B-95C19B288E4DQ35646935-5142EDDE-D15B-4F78-9DE1-3BEC859FAEC1Q35759011-0FA2C9FA-507D-4C5F-B343-E8444368DDE0Q36782635-7A326CD1-1FFF-4463-8521-E0FB92B30B67Q37277357-55F77905-473D-47F8-A62D-EB23752355A4Q37834318-C5A7F9F1-8FEC-4357-AE91-0865FA6E5BEBQ38272526-EA366523-3E69-4C3B-A399-5E918B809FF3Q38628084-8D577D52-9559-4753-B26C-7EC2871C1834Q39818309-2CF5B68E-C8CF-4444-90D6-A8AE77DD930FQ39832372-50C1C4AB-E0B0-4343-A923-5C550E8DAA02Q39833562-9B88B2E3-10E9-4791-B202-69FA43A0B485Q39834459-2312DF23-9A47-48CF-AAC0-A222D4467307Q39848860-4576F3B7-27B3-4846-9726-23AF4111A127Q40286069-55DACBD8-868A-40DE-9BAD-C538441F8DE8Q41858315-7954AF35-C1C7-4C03-8EA7-BD9163A1B4FAQ46102812-7FE56520-CFE2-4E02-B152-412149266E53
P2860
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
@en
type
label
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
@en
prefLabel
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
@en
P2093
P2860
P356
P1476
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
@en
P2093
Nakamura S
Yamagishi J
P2860
P304
P356
10.1128/AAC.23.5.641
P407
P577
1983-05-01T00:00:00Z